You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
The Breathing for Life Trial: a randomised controlled trial of fractional exhaled nitric oxide (FENO)-based management of asthma during pregnancy and its impact on perinatal outcomes and infant and childhood respiratory health
|
|---|---|
| Published in |
BMC Pregnancy and Childbirth, May 2016
|
| DOI | 10.1186/s12884-016-0890-3 |
| Pubmed ID | |
| Authors |
Vanessa E. Murphy, Megan E. Jensen, Joerg Mattes, Michael J. Hensley, Warwick B. Giles, Michael J. Peek, Andrew Bisits, Leonie K. Callaway, Kirsten McCaffery, Helen L. Barrett, Paul B. Colditz, Sean K. Seeho, John Attia, Andrew Searles, Christopher Doran, Heather Powell, Peter G. Gibson |
| Abstract |
Asthma exacerbations are common during pregnancy and associated with an increased risk of adverse perinatal outcomes. Adjusting asthma treatment based on airway inflammation rather than symptoms reduces the exacerbation rate by 50 %. The Breathing for Life Trial (BLT) will test whether this approach also improves perinatal outcomes. BLT is a multicentre, parallel group, randomised controlled trial of asthma management guided by fractional exhaled nitric oxide (FENO, a marker of eosinophilic airway inflammation) compared to usual care, with prospective infant follow-up. Women with physician-diagnosed asthma, asthma symptoms and/or medication use in the previous 12 months, who are 12-22 weeks gestation, will be eligible for inclusion. Women randomised to the control group will have one clinical assessment of their asthma, including self-management education. Any treatment changes will be made by their general practitioner. Women randomised to the intervention group will have clinical assessments every 3-6 weeks during pregnancy, and asthma treatments will be adjusted every second visit based on an algorithm which uses FENO to adjust inhaled corticosteroid (ICS) dose (increase in dose when FENO >29 parts per billion (ppb), decrease in dose when FENO <19 ppb, and no change when FENO is between 19 and 29 ppb). A long acting beta agonist (LABA) will be added when symptoms remain uncontrolled. Both the control and intervention groups will report on exacerbations at a postpartum phone interview. The primary outcome is adverse perinatal outcome (a composite measure including preterm birth, intrauterine growth restriction, neonatal hospitalisation at birth or perinatal mortality), assessed from hospital records. Secondary outcomes will be each component of the primary outcome, maternal exacerbations requiring medical intervention during pregnancy (both smokers and non-smokers), and hospitalisation and emergency department presentation for wheeze, bronchiolitis or croup in the first 12 months of infancy. Outcome assessment and statistical analysis of the primary outcome will be blinded. To detect a reduction in adverse perinatal outcomes from 35 % to 26 %, 600 pregnant women with asthma per group are required. This trial will provide evidence for the effectiveness of a FENO-based management strategy in improving perinatal outcomes in pregnant women with asthma. If successful, this would improve the management of pregnant women with asthma worldwide. Australian New Zealand Clinical Trials Registry ACTRN12613000202763 . |
Mendeley readers
The data shown below were compiled from readership statistics for 173 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Unknown | 172 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 31 | 18% |
| Student > Ph. D. Student | 21 | 12% |
| Researcher | 15 | 9% |
| Student > Bachelor | 12 | 7% |
| Student > Doctoral Student | 10 | 6% |
| Other | 31 | 18% |
| Unknown | 53 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 29% |
| Nursing and Health Professions | 25 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 5% |
| Social Sciences | 6 | 3% |
| Psychology | 4 | 2% |
| Other | 20 | 12% |
| Unknown | 59 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2021.
All research outputs
#7,801,448
of 23,685,936 outputs
Outputs from BMC Pregnancy and Childbirth
#2,146
of 4,362 outputs
Outputs of similar age
#118,823
of 329,027 outputs
Outputs of similar age from BMC Pregnancy and Childbirth
#31
of 59 outputs
Altmetric has tracked 23,685,936 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,362 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,027 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.